Imaging and management of Prostate cancer

Publication date: Available online 18 February 2020Source: Seminars in Ultrasound, CT and MRIAuthor(s): Devaki Shilpa Sudha Surasi, Brian Chapin, Chad Tang, Gregory Ravizzini, Tharakeswara Kumar BathalaAbstractProstate cancer (PCa) is the most common non-cutaneous malignancy in men and the second leading cause of cancer related death in the United States. Men with clinical suspicion of PCa undergo tissue sampling and based on features including the Gleason score, Prostate Specific antigen (PSA) levels and clinical tumor (T) stage, patients are risk stratified into 6 major groups based on National Comprehensive Cancer Network (NCCN) guidelines. This forms the basis for deciding imaging and management. Active surveillance is the preferred approach for less aggressive tumors. Surgery or radiation +/- androgen deprivation therapy continue to be the primary treatment options for localized disease. Imaging plays a critical role in the diagnosis, staging and management of PCa. Multiparametric MRI (mpMRI) is currently the imaging modality of choice for locoregional staging. Magnetic Resonance Imaging (MRI) and Computed tomography (CT) and bone scan remain the preferred modalities for evaluation of nodal, soft tissue and bone metastases respectively. Advanced Positron Emission Tomography (PET) imaging using novel radiotracers are being developed but are not yet integrated in the diagnostic guidelines for initial staging. In this review, we will discuss the imaging and treatment algori...
Source: Seminars in Ultrasound, CT and MRI - Category: Radiology Source Type: research